Published in J Biol Chem on September 18, 2003
Structure-Activity Relationship Studies of N- and C-Terminally Modified Secretin Analogs for the Human Secretin Receptor. PLoS One (2016) 1.39
Molecular basis of secretin docking to its intact receptor using multiple photolabile probes distributed throughout the pharmacophore. J Biol Chem (2011) 1.06
Spatial approximation between secretin residue five and the third extracellular loop of its receptor provides new insight into the molecular basis of natural agonist binding. Mol Pharmacol (2008) 1.06
Mapping ligand-receptor interfaces: approaching the resolution limit of benzophenone-based photoaffinity scanning. Chem Biol Drug Des (2008) 1.01
NMR structure of the first extracellular domain of corticotropin-releasing factor receptor 1 (ECD1-CRF-R1) complexed with a high affinity agonist. J Biol Chem (2010) 0.97
Structural and functional insights into the juxtamembranous amino-terminal tail and extracellular loop regions of class B GPCRs. Br J Pharmacol (2014) 0.88
Evolutionarily conserved residues at glucagon-like peptide-1 (GLP-1) receptor core confer ligand-induced receptor activation. J Biol Chem (2011) 0.88
Ligand binding pocket formed by evolutionarily conserved residues in the glucagon-like peptide-1 (GLP-1) receptor core domain. J Biol Chem (2015) 0.87
Structural and molecular conservation of glucagon-like Peptide-1 and its receptor confers selective ligand-receptor interaction. Front Endocrinol (Lausanne) (2012) 0.81
Ligand binding and activation of the secretin receptor, a prototypic family B G protein-coupled receptor. Br J Pharmacol (2012) 0.78
Insights into the impact of phenolic residue incorporation at each position along secretin for receptor binding and biological activity. Regul Pept (2012) 0.76
Effects of pH and temperature on photoaffinity labeling of Family B G protein-coupled receptors. Regul Pept (2009) 0.75
SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem (2008) 4.16
AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab (2011) 3.98
Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev (2010) 3.27
Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology (2002) 2.76
Supportive versus palliative care: what's in a name?: a survey of medical oncologists and midlevel providers at a comprehensive cancer center. Cancer (2009) 2.58
International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev (2003) 2.25
HIV and syphilis prevalence among men who have sex with men: a cross-sectional survey of 61 cities in China. Clin Infect Dis (2013) 2.24
SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J Biol Chem (2010) 2.20
AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol (2010) 2.11
Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res (2007) 1.73
Possible endogenous agonist mechanism for the activation of secretin family G protein-coupled receptors. Mol Pharmacol (2006) 1.72
Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver. FASEB J (2011) 1.65
Association between a name change from palliative to supportive care and the timing of patient referrals at a comprehensive cancer center. Oncologist (2011) 1.61
An EF-hand in the sodium channel couples intracellular calcium to cardiac excitability. Nat Struct Mol Biol (2004) 1.59
Review of HIV and other sexually transmitted infections among female sex workers in China. AIDS Care (2011) 1.57
Transmembrane segment IV contributes a functionally important interface for oligomerization of the Class II G protein-coupled secretin receptor. J Biol Chem (2007) 1.55
Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol (2010) 1.49
Phosphorylation of 338SSYY341 regulates specific interaction between Raf-1 and MEK1. J Biol Chem (2002) 1.48
Discharge outcomes and survival of patients with advanced cancer admitted to an acute palliative care unit at a comprehensive cancer center. J Palliat Med (2010) 1.48
Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations. Proc Natl Acad Sci U S A (2013) 1.46
The lack of standard definitions in the supportive and palliative oncology literature. J Pain Symptom Manage (2011) 1.30
Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. Cancer Res (2006) 1.29
Spatial approximation between the amino terminus of a peptide agonist and the top of the sixth transmembrane segment of the secretin receptor. J Biol Chem (2003) 1.26
Constitutive formation of oligomeric complexes between family B G protein-coupled vasoactive intestinal polypeptide and secretin receptors. Mol Pharmacol (2005) 1.23
Erbin suppresses the MAP kinase pathway. J Biol Chem (2002) 1.23
Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling. J Biol Chem (2011) 1.22
Molecular approximation between a residue in the amino-terminal region of calcitonin and the third extracellular loop of the class B G protein-coupled calcitonin receptor. J Biol Chem (2004) 1.21
Impact of delirium and recall on the level of distress in patients with advanced cancer and their family caregivers. Cancer (2009) 1.20
A genome-wide association study in Han Chinese identifies a susceptibility locus for primary Sjögren's syndrome at 7q11.23. Nat Genet (2013) 1.19
Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation. J Biol Chem (2011) 1.19
Antineoplastic therapy use in patients with advanced cancer admitted to an acute palliative care unit at a comprehensive cancer center: a simultaneous care model. Cancer (2010) 1.19
Heterodimerization of type A and B cholecystokinin receptors enhance signaling and promote cell growth. J Biol Chem (2003) 1.17
Staggered Mesh Ewald: An extension of the Smooth Particle-Mesh Ewald method adding great versatility. J Chem Theory Comput (2009) 1.16
Molecular approximations between residues 21 and 23 of secretin and its receptor: development of a model for peptide docking with the amino terminus of the secretin receptor. Mol Pharmacol (2007) 1.16
Environment and mobility of a series of fluorescent reporters at the amino terminus of structurally related peptide agonists and antagonists bound to the cholecystokinin receptor. J Biol Chem (2002) 1.15
Modeling the transmembrane domain of bacterial chemoreceptors. Protein Sci (2002) 1.15
Three-dimensional models for beta-adrenergic receptor complexes with agonists and antagonists. J Med Chem (2003) 1.14
Mapping spatial approximations between the amino terminus of secretin and each of the extracellular loops of its receptor using cysteine trapping. FASEB J (2012) 1.13
Symptom distress, interventions, and outcomes of intensive care unit cancer patients referred to a palliative care consult team. Cancer (2009) 1.13
The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus. Circulation (2005) 1.13
Functional importance of a structurally distinct homodimeric complex of the family B G protein-coupled secretin receptor. Mol Pharmacol (2009) 1.12
Dimeric arrangement of the parathyroid hormone receptor and a structural mechanism for ligand-induced dissociation. J Biol Chem (2010) 1.10
A misspliced form of the cholecystokinin-B/gastrin receptor in pancreatic carcinoma: role of reduced sellular U2AF35 and a suboptimal 3'-splicing site leading to retention of the fourth intron. Cancer Res (2002) 1.10
Dimerization in the absence of higher-order oligomerization of the G protein-coupled secretin receptor. Biochim Biophys Acta (2008) 1.10
Early mechanistic events in biotin dissociation from streptavidin. Nat Struct Biol (2002) 1.08
Simulations of a protein crystal: explicit treatment of crystallization conditions links theory and experiment in the streptavidin-biotin complex. Biochemistry (2008) 1.08
Simulation of nitroxide electron paramagnetic resonance spectra from brownian trajectories and molecular dynamics simulations. Biophys J (2008) 1.07
Spatial approximation between secretin residue five and the third extracellular loop of its receptor provides new insight into the molecular basis of natural agonist binding. Mol Pharmacol (2008) 1.06
Molecular basis of secretin docking to its intact receptor using multiple photolabile probes distributed throughout the pharmacophore. J Biol Chem (2011) 1.06
Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands. J Med Chem (2009) 1.06
Dynamics of the streptavidin-biotin complex in solution and in its crystal lattice: distinct behavior revealed by molecular simulations. J Phys Chem B (2009) 1.06
Symptom distress in advanced cancer patients with anxiety and depression in the palliative care setting. Support Care Cancer (2008) 1.06
Overnutrition and maternal obesity in sheep pregnancy alter the JNK-IRS-1 signaling cascades and cardiac function in the fetal heart. FASEB J (2010) 1.05
Enzymatic properties and nucleotide and amino acid sequences of a thermostable beta-agarase from the novel marine isolate, JAMB-A94. Biosci Biotechnol Biochem (2004) 1.05
Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1. Antimicrob Agents Chemother (2007) 1.05
Pattern of intra-family hetero-oligomerization involving the G-protein-coupled secretin receptor. J Mol Neurosci (2008) 1.05
AMPK exerts dual regulatory effects on the PI3K pathway. J Mol Signal (2010) 1.05
Secretin receptor oligomers form intracellularly during maturation through receptor core domains. Biochemistry (2006) 1.05
PEPFAR's evolving HIV prevention approaches for key populations--people who inject drugs, men who have sex with men, and sex workers: progress, challenges, and opportunities. J Acquir Immune Defic Syndr (2012) 1.04
Differential effects of modification of membrane cholesterol and sphingolipids on the conformation, function, and trafficking of the G protein-coupled cholecystokinin receptor. J Biol Chem (2004) 1.04
Molecular basis of glucagon-like peptide 1 docking to its intact receptor studied with carboxyl-terminal photolabile probes. J Biol Chem (2009) 1.04
Importance of the amino terminus in secretin family G protein-coupled receptors. Intrinsic photoaffinity labeling establishes initial docking constraints for the calcitonin receptor. J Biol Chem (2003) 1.04
Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor. Mol Pharmacol (2002) 1.04
Cloning, expression, and characterization of a glycoside hydrolase family 86 beta-agarase from a deep-sea Microbulbifer-like isolate. Appl Microbiol Biotechnol (2004) 1.04
Silencing of secretin receptor function by dimerization with a misspliced variant secretin receptor in ductal pancreatic adenocarcinoma. Cancer Res (2002) 1.03
Transmembrane segment peptides can disrupt cholecystokinin receptor oligomerization without affecting receptor function. Biochemistry (2006) 1.03
Human immunodeficiency virus knowledge and attitudes among hospital-based healthcare professionals in Guangxi Zhuang Autonomous Region, People's Republic of China. Infect Control Hosp Epidemiol (2003) 1.02
Spatial approximations between residues 6 and 12 in the amino-terminal region of glucagon-like peptide 1 and its receptor: a region critical for biological activity. J Biol Chem (2010) 1.02
Structure and function of Norrin in assembly and activation of a Frizzled 4-Lrp5/6 complex. Genes Dev (2013) 1.01
Secretin occupies a single protomer of the homodimeric secretin receptor complex: insights from photoaffinity labeling studies using dual sites of covalent attachment. J Biol Chem (2010) 1.01
Cytoplasmic CUL9/PARC ubiquitin ligase is a tumor suppressor and promotes p53-dependent apoptosis. Cancer Res (2011) 1.00
Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation. Mol Pharmacol (2011) 1.00
Streptavidin and its biotin complex at atomic resolution. Acta Crystallogr D Biol Crystallogr (2011) 1.00
Molecular characterization and distribution of motilin family receptors in the human gastrointestinal tract. J Gastroenterol (2006) 0.99
Retinoic acid receptor β stimulates hepatic induction of fibroblast growth factor 21 to promote fatty acid oxidation and control whole-body energy homeostasis in mice. J Biol Chem (2013) 0.99
Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor. Br J Pharmacol (2009) 0.99
Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors. Mol Endocrinol (2008) 0.98
Molecular dynamics simulations of arachidonic acid complexes with COX-1 and COX-2: insights into equilibrium behavior. Biochemistry (2006) 0.98
Importance of each residue within secretin for receptor binding and biological activity. Biochemistry (2011) 0.98
Quiescin sulfhydryl oxidase 1 promotes invasion of pancreatic tumor cells mediated by matrix metalloproteinases. Mol Cancer Res (2011) 0.98
Vulnerability in Popular Molecular Dynamics Packages Concerning Langevin and Andersen Dynamics. J Chem Theory Comput (2008) 0.98